2056-40-8

Basic information

• Product Name: 2-(azocan-1-yl)ethanol
• CAS NO: 2056-40-8
• Molecular Formula: C₉H₁₉NO
• Molecular Weight: 157.2533
• Mol File: 2056-40-8.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 251.9°C at 760 mmHg
• Flash Point: 107.8°C
• Density: 0.935g/cm³
• Vapor Pressure: 0.00311mmHg at 25°C
• Refractive Index: 1.467
• CAS DataBase Reference: 2-(azocan-1-yl)ethanol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(azocan-1-yl)ethanol(2056-40-8)
• EPA Substance Registry System: 2-(azocan-1-yl)ethanol(2056-40-8)

Safety Data

• Hazardous Substances Data: 2056-40-8(Hazardous Substances Data)

Usage

Appearance

Colorless liquid

Odor

Faint amine-like

Uses

+ Surfactant
+ Emulsifier
+ Dispersing agent
+ Metalworking fluids
+ Lubricants
+ Corrosion inhibitors
+ Agrochemicals production
+ Pharmaceuticals production
+ Polymer additives

Toxicity

Low, but requires proper handling and safety precautions

Upstream product

• 1121-92-2 heptamethyleneimine 
• 540-51-2 2-bromoethanol 
• 222722-38-5 1-(2-((tert-butyldimethylsilyl)oxy)ethyl)azocane 
• 502-42-1 cycloheptanone 
• 673-66-5 7-amino-heptanoic acid lactam 
• 64818-36-6 5-hexenyl methanesulfonate 
• 201230-82-2 carbon monoxide 
• 238755-60-7 2-(hex-5-enylamino)ethanol 

Downstream Products

• 2056-41-9 1-(2-chloro-ethyl)-octahydro-azocine; hydrochloride 
• 123103-19-5 diphenyl-acetic acid-(2-hexahydroazocin-1-yl-ethyl ester) 

Relevant articles and documents

ESTROGEN RECEPTOR MODULATORS AND USES THEREOF

Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Preparation and in vitro pharmacology of 5-HT4 receptor ligands. Partial agonism and antagonism of metoclopramide analogous benzoic esters

Alicyclic ester analogues of the gastroprokinetic benzamide metoclopramide (1) and its ester congener SDZ 205557 (2), a 5-HT4 receptor antagonist, were prepared by O-alkylation of 4-amino-5-chloro-2-methoxybenzoate with N-(2-chloroethyl) substituted alicyclic amines. The bromo and iodo analogue of compound 13b (2-(1-piperidinyl)ethyl 4-amino-5-chloro-2-methoxybenzoate) were obtained by halogenation of dechloro-13b with N-halogenated succinimides. The series was evaluated in functional in vitro assays with regard to affinity for serotoninergic 5-HT4, 5-HT3 and muscarinic M3 receptors. The affinities for 5-HT3 and M3 receptors were below 6.0 (pK(B) or pA2). On 5-HT4 receptors in guinea-pig ileal longitudinal muscle and rat oesophagus, the majority of compounds revealed partial 5-HT4 receptor agonism susceptible to blockade by SDZ 205557, a reference 5-HT4 receptor antagonist (pK(B) = 7.25-7.73 (guinea-pig ileum) and 7.09-7.43 (rat oesophagus)). The relative agonist potency was in the range of 5-303% (5-HT: 100%). Compound 13b and its bromo analogue 17 were the most potent esters of the series. The enantiomers of 13g ((R)- and (S)-2-(2-methyl-1-piperidinyl)ethyl 4-amino-5-chloro-2-methoxybenzoate) interacted stereoselectively with 5-HT4 receptors and displayed enantiomeric potency ratios (R)/(S) of 4.3-8.7. There was an excellent correlation between (a) antagonist affinity on guinea-pig ileum and rat oesophagus, (b) relative agonist potency on guinea-pig ileum and rat oesophagus, and (c) between antagonist affinity and relative agonist potency within each assay (r2 > 0.91). The new compounds may serve as academic tools in evaluating the functional role of 5-HT4 receptors. The selective partial 5-HT4 receptor agonists presented in this paper may be useful to restore physiological motility and secretion in the gut with reduced or absent propensity to elicit tachycardia and desensitization of the intestinal target receptor.